



***TRANSNASAL DELIVERABLES, INC.***  
**PHARMACEUTICAL DELIVERY SYSTEMS**

Abraham Wien, Pres.  
Terry Burka, CEO

Florida Office 2141 NW 1 <sup>st</sup> Place Boca Raton, FL 33431 c/ 605-609-9093 aw@transnasal.com	Virginia Office 5717 Waterloo Bridge Cir. Haymarket, VA. 20169 c/ 949-610-3345 tb@transnasal.com
---	--

**RE: *Confidential and Limited* Life Sciences Medical Device IP Opportunity**

**TO: Interested Intellectual Property NFT Purchaser**

Dear Potential Purchaser,

Thank you for requesting *TransNasal Deliverables'* Business Plan that describes a remarkable medical device which is capable of increasing nasal airway passage by gently spreading the mucous membranes. Moreover, the device's apex tips can be customized to transnasally deliver both, prescription drugs and over-the-counter drugs. The Plan includes summaries of research, operating and marketing objectives, and pro forma financial analyses. To request the Plan, please sign and return the NDA/disclaimer below to [info@transnasal.com](mailto:info@transnasal.com).

Feel free to contact us with questions using the link below.

Terry

Terry Burka, CEO  
Transnasal Deliverables, Inc.



## **Confidentiality, Reservation of Rights, Financial Disclaimer**

**TransNasal Deliverables, Inc.** (“TDI”; “Owner”) is a seed-stage medical device development and pharmaceutical delivery company structured to profit from:

- 1) Retail sales of the Nasal Dilator
- 2) Retail sales of the Nasal Dilator Medication Delivery System as modified with over-the-counter pharmaceuticals
- 3) Retail sales of the Nasal Dilator Medication Delivery System as modified with prescription-based pharmaceuticals

Information and statistics in this Executive Summary have been obtained from sources believed to be reliable, but are not guaranteed to be accurate or complete, and are subject to change.

### **Confidential Executive Summary**

As a recipient of one of the numbered Executive Summaries, you agree to the following:

This Agreement applies to all Confidential Information disclosed by one party (“Disclosing Party”) to the other party (“Recipient”). Unless otherwise expressly provided herein, the Receiving Party shall strictly maintain the secrecy of any information contained herein, all of which is considered of a sensitive nature, and thus is regarded as “Confidential Information.” Except with prior written consent of the Disclosing Party, the Receiving Party shall only be permitted to use the Confidential Information to jointly assess equity or debt capitalization and cooperative business opportunities. The Disclosing Party does not grant any express or implied right to the Receiving Party to any patents, model utility rights, design rights, trademarks, copyrights, financial spreadsheets and formulas, business forecasts, technology, scientific conclusions or forecasts, trade secrets and/or other intellectual property rights (collectively, “Intellectual Property Rights”). The Recipient shall not assign or transfer any rights or obligation under this Agreement without prior written consent of the Disclosing Party. Information is being provided for internal evaluation only. The Receiving Party shall not disclose the information contained herein to anyone who is not an officer, director, or member of the board. If the Receiving Party requires contractor or third-party evaluation, sufficient notice will be provided to the Disclosing Party for the purpose of its obtaining a discrete non-disclosure and confidentiality agreement from that contractor or third-party. The Receiving Party shall notify the Disclosing Party immediately upon discovery of any unauthorized use or disclosure of the Confidential Information. The Receiving Party shall not reverse engineer, decompile or disassemble the Confidential Information disclosed herein. The Receiving Party shall be liable to the Disclosing Party for any damage resulting from unauthorized use or disclosure of the Confidential Information, whether unintentional, or upon fault or negligence of the Receiving Party. The confidential nature of this Executive Summary shall be in full force and effect for two (2) years commencing from the date of receipt as indicated at the end of this Agreement (“Effective Date”) or as indicated within the transmittal email. This Agreement shall be governed by the laws of the State of Florida.

### **Reservation of Rights**

All rights reserved. TRANSNASAL DELIVERABLES, INC. is an exclusive service mark. No part of this publication may be reproduced, stored on any Internet-based public retrieval system, on any cloud-based network, or transmitted in any form or by any means without the express written permission of *Transdermal Deliverables, Inc.*

### **Forward Looking Financial Statement Disclaimer**

This Summary and Business Plan is not an offer to sell public securities, nor a solicitation of any offer to



purchase securities in any jurisdiction where the offer or sale is not permitted. It does not purport to be all-inclusive, nor contain all the information that a potential investor may desire. All information contained herein is provided “as-is” and without any warranty, express or implied, regarding its accuracy, completeness, or performance. Liability is disclaimed by *Transdermal Deliverables, Inc.* which may be based on such information, e.g., errors therein or omissions therefrom. All financial data contained herein is unaudited.

Forecasts and pro forma information contained herein represent estimates based on assumptions considered reasonable under the circumstances. No representations or warranties, expressed or implied, are made that the actual results will conform to forecasts. This Executive Summary and Business Plan contains “forward-looking financial statements,” including statements concerning the company’s outlook for 2017 to 2027, and a number of new services that are expected to be added in subsequent years. It also includes business strategies and their anticipated results, and similar statements concerning anticipated future events and expectations that are not historical facts. You can identify these statements by forward-looking words, such as “may,” “will,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “continue,” or similar words.

Forward-looking statements in this Summary and Business Plan are subject to numerous risks and uncertainties which could cause actual results to materially vary from those expressed in, or implied by, the statements herein. Such risks may include the effects of changing economic conditions, such as competitive conditions in the biotechnical industries, the impact of government regulations, and the availability of capital to finance growth.

There can be no assurance that required regulatory approvals will be obtainable.

This Summary and Business Plan is intended to provide information regarding an investment opportunity and does not constitute advice or recommendations.

To receive the Business Plan, please fill out the form below and return this *Confidentiality, Reservation of Rights, Financial Disclaimer* to [info@transnasal.com](mailto:info@transnasal.com). Thank you.

IN WITNESS WHEREOF, this Confidentiality Agreement is duly executed and delivered by its proper and duly authorized agent as of the date set forth below.

**RECIPIENT AGREEMENT**

---

Signature

---

Print Name

---

Title

---

Date